SI-BONE (SIBN) Azione Prezzo
SI-BONE Prezzo
Il fatturato è cresciuto a un tasso composto del 13,9% annuo negli ultimi 13 anni, raggiungendo 200,93 Mio. USD. Il margine netto di SI-BONE si attesta al -9,4%, in aumento rispetto al -62,8% di alcuni anni fa. Gli analisti fissano un target di prezzo mediano di 23,00 USD, ovvero il 1,9% sotto il prezzo attuale. Su 15 analisti, 14 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
SI-BONE Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
SI-BONE Azione e analisi azionaria
Domande frequenti sull'azione SI-BONE
The business model of SI-BONE Inc is focused on developing minimally invasive surgical solutions for patients suffering from sacroiliac (SI) joint disorders. The company specializes in the design and manufacturing of medical devices, including the iFuse Implant System. SI-BONE's innovative approach involves utilizing advanced technology and expertise to address the biomechanical causes of SI joint dysfunction. By providing effective treatment options, SI-BONE aims to improve patients' quality of life and restore their mobility. As a leader in the field, SI-BONE Inc continues to prioritize research, innovation, and collaboration with healthcare professionals in order to offer cutting-edge solutions for SI joint disorders.
SI-BONE Inc is primarily active in the healthcare industry, specifically specializing in the development and commercialization of innovative medical devices for patients suffering from musculoskeletal disorders. The company focuses on providing minimally invasive, cutting-edge solutions for the diagnosis and treatment of conditions related to the sacroiliac joint. With their groundbreaking technology and dedication to improving patient outcomes, SI-BONE Inc has positioned itself as a leader in the healthcare sector, offering effective solutions for individuals in need of long-term relief from debilitating pain and discomfort.
The main competitors of SI-BONE Inc in the market are Zimmer Biomet Holdings Inc, Medtronic PLC, and NuVasive Inc.
SI-BONE Inc is a leading medical device company specializing in minimally invasive solutions for the treatment of sacroiliac (SI) joint dysfunction. Founded in 2008, SI-BONE has emerged as a pioneer in this field, revolutionizing the way SI joint pain is diagnosed and treated. The company's flagship product is the iFuse Implant System, which provides a durable and minimally invasive option for patients suffering from SI joint dysfunction. Backed by extensive clinical research and a commitment to innovation, SI-BONE Inc has quickly gained recognition as a trusted provider of SI joint solutions, improving the quality of life for countless patients worldwide.
SI-BONE Inc has achieved several significant milestones in their history. One noteworthy accomplishment is the FDA clearance of their iFuse Implant System, a minimally invasive surgical solution for sacroiliac joint fusion. This clearance allowed SI-BONE Inc to offer their innovative treatment to patients suffering from SI joint dysfunction. Additionally, the company went public in 2018, marking another milestone in their growth. SI-BONE Inc's dedication to research and development has led to advancements in medical technology and improved patient outcomes. They continue to make strides in the field of SI joint fusion and are committed to providing effective solutions for patients.
SI-BONE Inc is primarily present in the United States and Europe.
SI-BONE Inc represents a commitment to improving patient lives through innovative medical solutions. Their corporate philosophy revolves around providing minimally invasive technologies for the diagnosis, treatment, and management of musculoskeletal disorders. The company actively focuses on advancing the field of sacroiliac joint dysfunction (SIJD) treatment with their FDA-cleared iFuse Implant System, offering a comprehensive solution for patients suffering from SIJD. SI-BONE Inc values patient-centric care, clinical research, collaboration with healthcare professionals, and continuous innovation to enhance patient outcomes. With their dedication to addressing unmet medical needs and improving quality of life, SI-BONE Inc has emerged as a trusted leader in the field of musculoskeletal healthcare.
Gli analisti fissano attualmente un prezzo obiettivo medio di 23,00 USD per l’azione SI-BONE (mediana: 23,00 USD), pari a -4,7 % rispetto all’ultimo prezzo. Il consenso si basa su 15 giudizi di analisti.
15 analisti valutano attualmente l’azione SI-BONE: 14 raccomandano l’acquisto, 1 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per SI-BONE ricavi pari a 232,14 Mio. USD e un utile per azione di -0,34 USD.
Convertita al tasso di cambio attuale, l’azione SI-BONE quota 21,24 EUR (23,44 USD).
L’azione SI-BONE (SIBN) è quotata su 3 borse, tra cui: NASDAQ (SIBN), Frankfurt (2K3.F), München (2K3.MU).
SI-BONE Inc is a medical company specialized in the development and marketing of innovative medical products in the field of spinal surgery. The company was founded in 2008 and is headquartered in Santa Clara, California. SI-BONE Inc specializes in the treatment of degenerative spinal diseases, particularly chronic lower back pain caused by Sacroiliac Joint Dysfunction. This condition affects millions of people worldwide and can lead to significant limitations in daily life. The business model of SI-BONE Inc is based on the development and marketing of innovative medical products aimed at improving the effectiveness and efficiency of Sacroiliac Joint Fusion (SI Fusion). Through the development of new technologies and applications, the company has introduced numerous products that support both minimally invasive and traditional surgical procedures. The flagship product of SI-BONE Inc is the iFuse Implant System, which is considered the only approved method for Sacroiliac Joint Fusion. The iFuse Implant is a small, triangular implant that is inserted into the SI Joint and provides permanent fixation. The implant is made of titanium, known for its strength and biocompatibility. In addition to the iFuse Implant System, SI-BONE Inc also offers a variety of training programs and support services for surgeons and medical professionals. The company has established a comprehensive network of clinics and medical centers to facilitate access to its products and services and raise awareness of the effectiveness of Sacroiliac Joint Fusion. SI-BONE Inc has also built a strong presence in the global market and works closely with international distributors to distribute its products worldwide. The company has branches in Europe, the Middle East, Africa, Asia, and Latin America to meet the needs of its global customers. The business model of SI-BONE Inc benefits both patients and surgeons and medical professionals. By providing innovative medical products and support services, the company contributes to improving patients' quality of life and avoiding potentially irreversible damage to the spine.
Il attesa fatturato di SI-BONE ammonta a 232,14 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di SI-BONE ammonta a -14,97 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di SI-BONE è attualmente -68,13. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione SI-BONE.
Il rapporto prezzo/fatturato (P/S) di SI-BONE è attualmente 4,39. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione SI-BONE.
Il Quality Score AlleAktien per SI-BONE è 5/10.
L'ISIN di SI-BONE è US8257041090. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di SI-BONE è A2N7LY. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di SI-BONE è SIBN. Con questo simbolo di borsa vengono negoziate le azioni SI-BONE in borsa.
Azione SI-BONE
Gruppo di pari di SI-BONE
SI-BONE Ticker
SI-BONE FIGI
Altre metriche e analisi di SI-BONE in Deep Dive.
La nostra analisi azionaria dell'azione SI-BONE include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di SI-BONE. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: